drugset / Trial / NCT04005729

Cangrelor in Comatose Survivors of OHCA Undergoing Primary PCI

NCT04005729

RandomizedParallel-groupSingle-blindTreatment

Summary

The main objective of the trial is to find out if 4-hour continuous infusion of parenteral P2Y12 inhibitor cangrelor at the start of primary percutaneous coronary intervention (PCI) immediately and effectively suppresses platelet activity in comatose survivors of out-of-hospital cardiac arrest (OHCA). Half of the participants will receive the standard care of dual antiplatelet therapy - acetysalicylic acid and ticagrelor tablets via nasogastric or orogastric tube and the other half the standard care with additional cangrelor infusion at the start of the PCI.

Timeline

Start
2019-07-01
Primary completion
2021-11-27
Completion
2021-11-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Cangrelor Small molecule 4 ug/kg Intravenous